ERBB2 and breast carcinoma: These results are consistent with previous study by Muraro E, et al., wherein the breast cancer group with HER-2 negative, the serum lymphokine profile (IL-2, IL-6, IL-8) was significantly lower compared to controls and the lymphokine profiles (IL-2, IL-1, IL-6, IL-8, IL-10) were significantly lower compared to the group with HER-2 positive (8).